scholarly journals Induced pluripotent stem cells and personalized medicine: current progress and future perspectives

2011 ◽  
Vol 44 (4) ◽  
pp. 245 ◽  
Author(s):  
Yong Soon Chun ◽  
Kyunghee Byun ◽  
Bonghee Lee
Keyword(s):  
Stem Cells ◽  
Personalized Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Future Perspectives ◽  
Induced Pluripotent ◽  
And Personalized Medicine

scholarly journals Introduction to Induced Pluripotent Stem Cells: Advancing the Potential for Personalized Medicine

2011 ◽  
Vol 76 (3-4) ◽  
pp. 270-275 ◽  
Author(s):  
Johnathan D. Ebben ◽  
Michael Zorniak ◽  
Paul A. Clark ◽  
John S. Kuo
Keyword(s):  
Stem Cells ◽  
Personalized Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Induced Pluripotent

How induced pluripotent stem cells are redefining personalized medicine

Gene ◽  
2013 ◽  
Vol 520 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Leonardo M.R. Ferreira ◽  
Mohammed A. Mostajo-Radji
Keyword(s):  
Stem Cells ◽  
Personalized Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Induced Pluripotent

scholarly journals Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells

Cells ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 26 ◽  
Author(s):  
Theo Stoddard-Bennett ◽  
Renee Reijo Pera
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Personalized Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Substantia Nigra Pars Compacta ◽  
Model Organisms ◽  
Patient Specific ◽  
Induced Pluripotent

Parkinson’s Disease (PD) is an intractable disease resulting in localized neurodegeneration of dopaminergic neurons of the substantia nigra pars compacta. Many current therapies of PD can only address the symptoms and not the underlying neurodegeneration of PD. To better understand the pathophysiological condition, researchers continue to seek models that mirror PD’s phenotypic manifestations as closely as possible. Recent advances in the field of cellular reprogramming and personalized medicine now allow for previously unattainable cell therapies and patient-specific modeling of PD using induced pluripotent stem cells (iPSCs). iPSCs can be selectively differentiated into a dopaminergic neuron fate naturally susceptible to neurodegeneration. In iPSC models, unlike other artificially-induced models, endogenous cellular machinery and transcriptional feedback are preserved, a fundamental step in accurately modeling this genetically complex disease. In addition to accurately modeling PD, iPSC lines can also be established with specific genetic risk factors to assess genetic sub-populations’ differing response to treatment. iPS cell lines can then be genetically corrected and subsequently transplanted back into the patient in hopes of re-establishing function. Current techniques focus on iPSCs because they are patient-specific, thereby reducing the risk of immune rejection. The year 2018 marked history as the year that the first human trial for PD iPSC transplantation began in Japan. This form of cell therapy has shown promising results in other model organisms and is currently one of our best options in slowing or even halting the progression of PD. Here, we examine the genetic contributions that have reshaped our understanding of PD, as well as the advantages and applications of iPSCs for modeling disease and personalized therapies.

scholarly journals The Challenge of Bringing iPSCs to the Patient

2019 ◽  
Vol 20 (24) ◽  
pp. 6305 ◽  
Author(s):  
María del Carmen Ortuño-Costela ◽  
Victoria Cerrada ◽  
Marta García-López ◽  
M. Esther Gallardo
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Personalized Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Biomedical Research ◽  
Drug Screening ◽  
Pluripotent Stem Cells ◽  
Promising Area ◽  
Induced Pluripotent

The implementation of induced pluripotent stem cells (iPSCs) in biomedical research more than a decade ago, resulted in a huge leap forward in the highly promising area of personalized medicine. Nowadays, we are even closer to the patient than ever. To date, there are multiple examples of iPSCs applications in clinical trials and drug screening. However, there are still many obstacles to overcome. In this review, we will focus our attention on the advantages of implementing induced pluripotent stem cells technology into the clinics but also commenting on all the current drawbacks that could hinder this promising path towards the patient.

Sign in / Sign up

Export Citation Format

Share Document